Sean Harper - Amgen Insider

Amgen Inc -- USA Stock  

USD 183.55  0.05  0.0272%

Executive Vice President - Research and Development

Dr. Sean E. Harper is the Executive Vice President Research and Development of Amgen Inc. Dr. Harper joined the Company in 2002, and has held leadership roles in early development, medical sciences and global regulatory and safety
Age: 53  President Since 2012  Ph.D    
Harper served as Senior Vice President, Global Development and Corporationrationrationrate Chief Medical Officer from March 2007 to February 2012. Prior to joining the Company, Dr. Harper worked for five years at Merck Research Laboratories.

Sean Harper Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.32 % which means that it generated profit of $8.32 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 7.18 % meaning that it created $7.18 on every $100 dollars invested by stockholders.
The company currently holds 35.34 B in liabilities with Debt to Equity (D/E) ratio of 140.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amgen Inc has Current Ratio of 5.38 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Thomas FrinziAbbott Laboratories
Jared WatkinAbbott Laboratories
Deepak NathAbbott Laboratories
Michael PartridgeVertex Pharmaceuticals Incorpor
John HertiaBio Rad Laboratories Inc
Joseph ManningAbbott Laboratories
Jonathon KellermanAllergan plc
Georges VosAbbott Laboratories
Paul SilvaVertex Pharmaceuticals Incorpor
Michael CrowleyBio Rad Laboratories Inc
Robert FunckAbbott Laboratories
Wayne SwantonAllergan plc
Camille FarhatEndo International plc
Michael WarmuthAbbott Laboratories
Thomas GraneyVertex Pharmaceuticals Incorpor
Philippe SchaisonAllergan plc
Shawn SoderbergBio Rad Laboratories Inc
Paul NavarreAllergan plc
Terrance CoughlinEndo International plc
Robert FordAbbott Laboratories
Matthew MalettaEndo International plc

Entity Summary

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California. Amgen operates under Biotechnology classification in USA and traded on NASDAQ exchange. It employs 20800 people.Amgen Inc (AMGN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 20,800 people. Amgen is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Fund Screener Now

Fund Screener

Find activelly-traded funds from around the world traded on over 30 global exchanges
Hide  View All  NextLaunch Fund Screener
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Amgen Inc to your portfolio

Top Management

Amgen Inc Leadership Team
Frank Herringer, Director
Francois Carbonnel, Director
Rebecca Henderson, Director, Ph.D
Annette Such, Executive
Sanders Williams, Director
Vance Coffman, Director, Ph.D
Tyler Jacks, Director, Ph.D
Brian McNamee, President
Gregory Garland, Director
Charles Holley, Director
Esteban Santos, President
Jonathan Graham, President
Sean Harper, President, Ph.D
Ellen Kullman, Director
Frank Biondi, Director
Arvind Sood, Executive
David Meline, CFO
Ronald Sugar, Director
Stuart Tross, President
Robert Bradway, Chairman
Wanda Austin, Director
Robert Eckert, Director
Madhavan Balachandran, EVP
Lori Johnston, President
Cynthia Patton, President
Greg Garland, Director
Judith Pelham, Director
David Baltimore, Director, Ph.D
Fred Hassan, Director
David Piacquad, President
Anthony Hooper, EVP

Stock Performance

Amgen Performance Indicators